Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile

Br J Haematol. 2020 Feb;188(4):483-485. doi: 10.1111/bjh.16214. Epub 2019 Sep 30.

Authors

Clifton C Mo¹, Paul G Richardson¹

Affiliation

¹ Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 31566715
DOI: 10.1111/bjh.16214

No abstract available

Keywords: lenalidomide; pomalidomide; refractory multiple myeloma.

Publication types

Editorial
Comment

MeSH terms

Dexamethasone
Humans
Lenalidomide*
Multiple Myeloma*
Thalidomide / analogs & derivatives
Treatment Failure

Substances

Thalidomide
Dexamethasone
pomalidomide
Lenalidomide